Pharnext Reports Financial Results for Year-End 2017
Pharnext SA (Paris:ALPHA) (FR00111911287 – ALPHA), a French biopharmaceutical company pioneering a new approach to developing innovative drug combinations based on Big Data genomics and Artificial Intelligence, today reported its financial and operational results for the year ended December 31, 2017.
2017 KEY EVENTS
During 2017, Pharnext continued its international Phase 3 trial of PXT3003 for the treatment of Charcot-Marie-Tooth type 1A (CMT1A) disease. This pivotal 15-month trial is being conducted at 29 sites including 17 in Europe, 11 in the U.S. and one in Canada.
In September 2017, the independent Data Safety Monitoring Board (DSMB) completed its second pre-specified safety evaluation of PXT3003. Based on a review of safety data from all randomized patients, the DSMB recommended Pharnext continue the study as planned.
In November 2017, two additional interim analyses were conducted. These consisted of a blind variability analysis followed by a futility analysis. The results indicated that the PLEO-CMT study could continue according to the original plan, without having to increase the trial size.
In March 2017, Pharnext initiated an open-label extension study, which includes patients that completed the double-blind PLEO-CMT study. All patients received one of two doses of PXT3003 over an additional nine-month period. The initial results from this extension study are expected in the second quarter of 2019.
In May 2017, Pharnext signed a strategic agreement with Tasly Pharmaceutical (Shanghai: 600535), an organization ranked amongst China’s top 10 pharmaceutical companies. This partnership included three components: a financial investment by Tasly in Pharnext comprised of €5 million in shares and €15 million in convertible bonds; the development of a new pipeline of synergistic combinations through a joint-venture; and the license of Pharnext’s lead product PXT3003 to the joint-venture for commercialization in the Chinese market.
In March 2017, Pharnext signed a research and development (R&D) agreement with biotechnology company Galapagos NV (NASDAQ: GLPG). The primary aim of this agreement is to generate a pipeline of novel synergistic drug combinations in a broad set of indications.
SELECTED FINANCIAL INFORMATION
The main elements of the year-end 2017 financials are set out in the table below: These are taken from the financial statements drawn up under IFRS, which were approved by the Board of Directors at its meeting on April 12, 2017. The audit procedures have been carried out and the auditors’ report relating to the certification of the accounts is in the process of being issued. The full financial statements are available on the Company’s website: www.pharnext.com .
|Selected financial information (under IFRS)|
|In thousands of euros||2017||2016|
|Research and development expenses||(15,529)||(13,647)|
|Basic earnings per share (in €)||(2)||(2.1)|
|Net cash flows used in operating activities||(18,800)||(12,553)|
|Net cash flows used in financing activities||15,361||26,902|
|Net cash movement||-4,215||13,581|
|Cash and cash equivalents at the end of the period||12,454||16,670|
Operating revenues for 2017 were mainly generated by the Company’s research tax credit (€3.9m in 2017) and subsidies.
The increase in research and development expenses were directly linked to the ramp-up of the PXT3003 Phase 3 clinical trial.
Financial income for 2017 was impacted by the recognition under financial expenses of the convertible bond issue in July for Tasly.
Net cash flows used in operating activities totalled €18.8m in 2017. The increase compared to the previous period was primarily the result of the Phase 3 roll-out.
Net cash flows used in financing activities in 2017 primarily comprised the €5m capital increase and the issue of €15m in convertible bonds for Tasly. In 2017, loan repayments and payment of interest charges and transaction costs on borrowing totalled €5.2m.
ANTICIPATED UPCOMING MILESTONES
Pharnext will announce the results from PLEO-CMT, the Phase 3 clinical trial for its drug candidate PXT3003 in CMT1A, during the second half of 2018.
Beyond the 15-month PLEO-CMT study, patients will continue treatment in a 9-month follow-up extension study designed to assess the long-term safety of PXT3003. This follow-up extension study, which began in March 2017, will continue throughout the year. The initial results are expected in the second quarter of 2019.
Pharnext is planning to launch a Phase 2b pediatric clinical trial for PXT3003 in CMT1A in Europe and the United States.
In addition, after obtaining promising preliminary results in the Phase 2a trial for PXT864 in Alzheimer's disease and data in other neurodegenerative diseases, the Company has identified two additional strategic priorities for 2018:
- Prioritize and identify new orphan indications to launch internal Phase 2a studies;
- Continue to develop strategic collaborations in common indications.
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics: Pharnext has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected before the end of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm based on Big Data genomics and Artificial Intelligence: PLEOTHERAPY™. The Company identifies and develops synergistic combinations of drugs. These PLEODRUG™ offer several key advantages: efficacy, safety and protected intellectual property. The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).
For more information, visit www.pharnext.com
This press release contains certain forward-looking statements concerning Pharnext and its business. Such forward-looking statements are based on assumptions that Pharnext considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the Document de référence filed with the Autorité des Marchés Financiers (AMF- French Financial Market Authority) on July 28, 2016 under no. R.16-069 and to changes in economic conditions, financial markets and the markets in which Pharnext operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Pharnext or not currently considered material by Pharnext. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Pharnext to be materially different from such forward-looking statements.
This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Pharnext shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Amit Kohli, +33 (0)1 41 09 22 30
Chief Operating Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212-362-1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Media Relations (Europe)
Caroline Carmagnol, +33 (0)1 44 54 36 66
Media Relations (U.S.)
Kate Barrette, +1-212-223-0561
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Schlumberger Announces Third-Quarter 2018 Results Conference Call21.8.2018 20:05 | Tiedote
Schlumberger Limited (NYSE:SLB) will hold a conference call on October 19, 2018 to discuss the results for the third quarter ending September 30, 2018. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (800) 288-8967 within North America or +1 (612) 333-4911 outside of North America approximately 10 minutes prior to the start of the call, and ask for the “Schlumberger Earnings Conference Call.” A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until November 19, 2018, and can be accessed by dialing +1 (800) 475-6701 withi
Amazon Game Studios Announces The Grand Tour Game21.8.2018 18:00 | Tiedote
Amazon.com (NASDAQ: AMZN) today announced that Jeremy Clarkson, Richard Hammond, and James May are bringing high-jinks and hot laps to PlayStation 4 and Xbox One in The Grand Tour Game, an episodic racing game based on the hit Prime Original series, The Grand Tour. Created by Amazon Game Studios, The Grand Tour Game transports players to exotic locations, where they'll drive the world's most interesting cars, and participate in the show's outrageous challenges. New episodes of The Grand Tour Game will be added weekly during Season 3 of the show, capturing cars, locations, and surprises from each week's episode. Visit www.playthegrandtourgame.com for more information. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180821005353/en/ The Grand Tour Game puts players behind the wheel of the cars from Season 3, and brings them to the iconic locations the hosts will visit this season, including The Grand Tour's signature Eboladrome
Andersen Global Expands in Africa with Oliveira & Associados21.8.2018 16:30 | Tiedote
Andersen Global continues its expansion in Africa through a Collaboration Agreement with Oliveira & Associados, a law firm based in Angola, founded by Formosa Oliveira in 2016. Andersen Global Chairman and Andersen Tax LLC CEO, Mark Vorsatz, commented, “The economy in Angola is one of the fastest growing in the world, and we are excited about adding this practice in a market that has a strong connection to Portugal and is strategic to our business in Portugal. Oliveira & Associados is an energetic and talented group, and with the addition of Isalcio Mahanjane e Associados in Mozambique last week, we have added key locations in our Portuguese and Iberian strategy.” With headquarters in Luanda, Oliveira & Associados provides legal services to both corporate and individual clients within Africa and globally. “Collaborating with Andersen Global will help us extend our reach as we develop and seamlessly deliver cross-border solutions,” remarked Formosa Oliveira. “With added tax and legal se
Mavenir Introduces RCS Business Messaging Partner Program to Enable MNO’s A2P Revenue Growth21.8.2018 16:00 | Tiedote
Mavenir, the world’s #1 messaging systems provider and a leader in Rich Communication Services (RCS)—with an 85% market share in North America—today announced its RCS Business Messaging Partner Program with 15 confirmed partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180821005089/en/ Mavenir’s RBM Chatbot (Photo: Business Wire) The Mavenir RCS Business Messaging (RBM) solution enables brands, aggregators, content providers, enterprises and MNOs to monetize RCS messaging technologies and provide rich, multimedia end-user experiences from the native messaging application on mobile devices. This global partner program is focused on accelerating the adoption of RCS multimedia messaging by creating a community of industry leading messaging partners to provide MNOs with a compelling business-to-consumer (B2C) messaging channel and become the platform of choice for advertisers, brands, content providers and enterprises to
Dynacor Announces First Quarterly Dividend Payment21.8.2018 15:03 | Tiedote
Dynacor Gold Mines Inc. (TSX: DNG) (OTC: DNGDF) (Dynacor or the Corporation) is pleased to announce today that its Board of Directors (Board) has approved the initiation of quarterly cash dividends to its shareholders and the declaration of the first cash dividend in the company's history. The dividend of CAD$ 0.01 per common share, is payable on October 1, 2018 to shareholders of record on September 20, 2018. Dynacor is one of the largest ore purchasing processors in Peru. With its new ore processing facility operating at near full capacity, the Corporation is forecasting 2018 to be its best year on record. Dynacor’s stable business model is proven to withstand the volatility of the gold price. The Corporation is free of debt, in a healthy financial situation and working towards its 30th consecutive quarter of profits. President and CEO Jean Martineau states, “Our team has worked very hard to build the Corporation to what it is today. Our solid financial situation and leadership posit
FAA Approves AerTrak for Boeing 757-200 Series Aircraft to Comply with Automatic Dependent Surveillance-Broadcast (ADS-B) Operations Mandate21.8.2018 15:00 | Tiedote
The Federal Aviation Administration (FAA) has issued a Supplemental Type Certificate (STC) for installation of AerSale®’s AerTrak™ system on Boeing 757-200 series aircraft (ST04011NY), to comply with the Automatic Dependent Surveillance-Broadcast (ADS-B) Operations rule, a critical part of the agency’s Next Generation Air Transportation System (NextGen). Beginning January 1, 2020, the FAA has mandated that aircraft operating in airspace defined by 14 CFR § 91.225 must be equipped with an ADS-B Out system that meets the minimum performance requirements of 14 CFR § 91.227. The FAA approved AerTrak for Boeing 737 NG series aircraft (ST04009NY) earlier this year. ADS-B provides enhanced navigational accuracy using precise tracking via global positioning satellite (GPS) signals. Reducing risk and improving safety, the technology increases navigational coverage, especially in remote areas beyond radar range. Additionally, ADS-B enables more direct flight plans, thereby saving time, costs, an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme